Cargando…
Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial
INTRODUCTION: This randomised controlled trial aims to compare the efficacy of warfarin replacement with apixaban without postoperative resumption of heparin with that of conventional heparin bridging in patients taking warfarin and scheduled to undergo endoscopic mucosal resection (EMR): specifical...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623266/ https://www.ncbi.nlm.nih.gov/pubmed/29018538 http://dx.doi.org/10.1136/bmjgast-2017-000152 |
_version_ | 1783268055464280064 |
---|---|
author | Yamada, Takuya Kada, Akiko Uraoka, Toshio Kuwai, Toshio Watanabe, Noriko Sasaki, Yoshihiro Mabe, Katsuhiro Takahashi, Yasuo Kagaya, Takashi Kimura, Toshihisa Hamada, Hiroshige Saito, Akiko M Harada, Naohiko |
author_facet | Yamada, Takuya Kada, Akiko Uraoka, Toshio Kuwai, Toshio Watanabe, Noriko Sasaki, Yoshihiro Mabe, Katsuhiro Takahashi, Yasuo Kagaya, Takashi Kimura, Toshihisa Hamada, Hiroshige Saito, Akiko M Harada, Naohiko |
author_sort | Yamada, Takuya |
collection | PubMed |
description | INTRODUCTION: This randomised controlled trial aims to compare the efficacy of warfarin replacement with apixaban without postoperative resumption of heparin with that of conventional heparin bridging in patients taking warfarin and scheduled to undergo endoscopic mucosal resection (EMR): specifically, by checking for reduction in proportion of postoperative bleeding following EMR. METHODS AND ANALYSIS: The multicentre, open-label randomised parallel-group, controlled intervention study regards patients taking warfarin who are scheduled to undergo colon EMR. Enrolled patients have been taking oral warfarin for non-valvular atrial fibrillation or venous thrombosis on an outpatient basis, and have been found to have a colorectal polyp (including adenoma or early-stage cancer) for which EMR was indicated. They are assigned to one of two groups. The primary endpoint is proportion of postoperative bleeding. The secondary endpoints are hospital stay length, therapeutic endoscopy outcomes such as proportion of en bloc resection, proportion of perforation, proportion of intraoperative bleeding, incidence of cerebral infarction/systemic embolism events, incidence of adverse events and serious adverse events, and proportion of postoperative therapeutic endoscopy. ETHICS AND DISSEMINATION: This trial was approved by the National Hospital Organization Central Review Board for Clinical Trials (19 April 2016). DISCUSSION: The paucity of reports with high evidence levels was considered problematic when the Japan Gastroenterological Endoscopy Society’s gastroenterological endoscopy guidelines were revised in 2012. The results of this trial will have high medical significance, as its data could serve as the basis for revisions in the next edition of the guidelines. TRIAL REGISTRATION NUMBER: This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) accepted from the International Committee of Medical Journal Editors (ICMJE). UMIN000021947; Pre-results. |
format | Online Article Text |
id | pubmed-5623266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56232662017-10-10 Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial Yamada, Takuya Kada, Akiko Uraoka, Toshio Kuwai, Toshio Watanabe, Noriko Sasaki, Yoshihiro Mabe, Katsuhiro Takahashi, Yasuo Kagaya, Takashi Kimura, Toshihisa Hamada, Hiroshige Saito, Akiko M Harada, Naohiko BMJ Open Gastroenterol Endoscopy INTRODUCTION: This randomised controlled trial aims to compare the efficacy of warfarin replacement with apixaban without postoperative resumption of heparin with that of conventional heparin bridging in patients taking warfarin and scheduled to undergo endoscopic mucosal resection (EMR): specifically, by checking for reduction in proportion of postoperative bleeding following EMR. METHODS AND ANALYSIS: The multicentre, open-label randomised parallel-group, controlled intervention study regards patients taking warfarin who are scheduled to undergo colon EMR. Enrolled patients have been taking oral warfarin for non-valvular atrial fibrillation or venous thrombosis on an outpatient basis, and have been found to have a colorectal polyp (including adenoma or early-stage cancer) for which EMR was indicated. They are assigned to one of two groups. The primary endpoint is proportion of postoperative bleeding. The secondary endpoints are hospital stay length, therapeutic endoscopy outcomes such as proportion of en bloc resection, proportion of perforation, proportion of intraoperative bleeding, incidence of cerebral infarction/systemic embolism events, incidence of adverse events and serious adverse events, and proportion of postoperative therapeutic endoscopy. ETHICS AND DISSEMINATION: This trial was approved by the National Hospital Organization Central Review Board for Clinical Trials (19 April 2016). DISCUSSION: The paucity of reports with high evidence levels was considered problematic when the Japan Gastroenterological Endoscopy Society’s gastroenterological endoscopy guidelines were revised in 2012. The results of this trial will have high medical significance, as its data could serve as the basis for revisions in the next edition of the guidelines. TRIAL REGISTRATION NUMBER: This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) accepted from the International Committee of Medical Journal Editors (ICMJE). UMIN000021947; Pre-results. BMJ Publishing Group 2017-09-15 /pmc/articles/PMC5623266/ /pubmed/29018538 http://dx.doi.org/10.1136/bmjgast-2017-000152 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Endoscopy Yamada, Takuya Kada, Akiko Uraoka, Toshio Kuwai, Toshio Watanabe, Noriko Sasaki, Yoshihiro Mabe, Katsuhiro Takahashi, Yasuo Kagaya, Takashi Kimura, Toshihisa Hamada, Hiroshige Saito, Akiko M Harada, Naohiko Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title | Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title_full | Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title_fullStr | Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title_full_unstemmed | Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title_short | Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
title_sort | replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial |
topic | Endoscopy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623266/ https://www.ncbi.nlm.nih.gov/pubmed/29018538 http://dx.doi.org/10.1136/bmjgast-2017-000152 |
work_keys_str_mv | AT yamadatakuya replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT kadaakiko replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT uraokatoshio replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT kuwaitoshio replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT watanabenoriko replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT sasakiyoshihiro replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT mabekatsuhiro replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT takahashiyasuo replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT kagayatakashi replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT kimuratoshihisa replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT hamadahiroshige replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT saitoakikom replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial AT haradanaohiko replacementofwarfarinwithanoveloralanticoagulantinendoscopicmucosalresectionamulticentreopenlabelrandomisedcontrolledtrial |